Moxifloxacin is named as an intervention in 9 current clinical trials in our India, China, Ireland and USA registers. 5 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is UMC Utrecht (1). The most-studied condition is Tuberculosis.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707 · Community-acquired Pneumonia, Influenza, COVID-19
|
Phase 3 | Recruiting | UMC Utrecht | Ireland, India |
|
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
NCT04722978 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
|
Phase 3 | Recruiting | Sun Yat-Sen University Cancer Center | China |
|
Shortened Regimen for Drug-susceptible TB in Children
NCT06253715 · ClinicalTrials.gov ↗ · Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node
|
Phase 3 | Recruiting | Johns Hopkins University | India |
|
A PAN-USR TB Multi-Center Trial
NCT06905522 · ClinicalTrials.gov ↗ · Pulmonary Tuberculosis
|
Phase 3 | Recruiting | Shenzhen Third People's Hospital | China |
|
A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
NCT07162116 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia With FLT3/ITD Mutation
|
Phase 1 | Recruiting | Shijiazhuang Yiling Pharmaceutical Co. Ltd | China |
|
Intensified Short Course Regimen for TBM in Adults
NCT05917340 · Tuberculous Meningitis
|
Phase 3 | Not yet open | Indian Council of Medical Research | India |
|
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
NCT03244072 · ClinicalTrials.gov ↗ · Endophthalmitis
|
Phase 2/3 | Not yet open | Jason Ahee, M.D. | USA |
|
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)
NCT07595042 · ClinicalTrials.gov ↗ · Tuberculosis
|
Phase 2 | Not yet open | National Institute of Allergy and Infectious Diseases (NIAID) | India |
|
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis๏ผContezolid, Delamanid and Bedaquiline Cohort
NCT06081361 · ClinicalTrials.gov ↗ · Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
|
Phase 3 | Active, closed | Beijing Chest Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
3 single-substance products containing Moxifloxacin on the HPRA medicines list.
| Lead sponsor | Trials |
|---|---|
| UMC Utrecht | 1 |
| Jason Ahee, M.D. | 1 |
| Indian Council of Medical Research | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
| Johns Hopkins University | 1 |
| Sun Yat-Sen University Cancer Center | 1 |
| Shenzhen Third People's Hospital | 1 |
| Beijing Chest Hospital | 1 |
| Shijiazhuang Yiling Pharmaceutical Co. Ltd | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in India | 4 | 2 |
| Clinical trials in China | 4 | 3 |
| Clinical trials in Ireland | 1 | 1 |
| Clinical trials in USA | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
9 current trials in our India, China, Ireland and USA registers name Moxifloxacin as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 9 trials are recruiting: 2 with sites in India, 3 with sites in China and 1 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
UMC Utrecht (1), Jason Ahee, M.D (1), Indian Council of Medical Research (1) and National Institute of Allergy and Infectious Diseases (NIAID) (1), among 9 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 3 single-substance products containing Moxifloxacin, for example Avelox 400 mg film-coated tablets (PCO Manufacturing Ltd.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 1 entry for Moxifloxacin: US FDA: resolved. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Moxifloxacin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Moxifloxacin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Moxifloxacin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.